Pharmacological management of non-alcoholic fatty liver disease: Atorvastatin versus pentoxifylline
نویسندگان
چکیده
In this study, we aimed to evaluate the efficacy of pentoxifylline and atorvastatin in the treatment of non-alcoholic fatty liver disease (NAFLD). The study included 98 patients with histologically confirmed NAFLD divided into 2 groups as follows: group I (57 dyslipidemic patients, receiving atorvastatin 20 mg/day and group II (41 non-dyslipidemic patients, treated with pentoxifylline, 800 mg/day). The present study was conducted for a mean of 32.8±3.4 weeks. For all patients, we determined the body mass index, a liver biopsy was performed, and we measured the serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), alkaline phosphatase (ALP), total cholesterol (TC) and triglycerides (TG) at the beginning and at the end of the study period. The NAFLD activity score (NAS) was used to evaluate the liver biopsies for steatosis, fibrosis and necroinflammation. The patients in group I exhibited a considerable reduction in ALT, AST, GGT, TC, AP and TG levels (P<0.0001). Histologically, there were no changes in fibrosis and necroinflammation, although the extent steatosis was reduced. The improvement in the ALT, AST and GGT values (P<0.05) in group II were similar to those in group I; however, no statistically significant decrease was noted in the levels of ALP, TC and TG in this group. Our results thus demonstrated that atorvastatin attenuated steatosis and improved liver function parameters in patients with NAFLD associated with dyslipidemia. Similar results were obtained in the non-dyslipidemic patients administered pentoxifylline.
منابع مشابه
ارزیابی تاثیر درمانی مکمل دارویی حصا-آ(HESA-A) همراه با آتورواستاتین بر روی کبد چرب غیر الکلی در موش صحرایی
Background and Objective: Fatty liver disease occurs due to disturbances in lipid metabolism (increased fat synthesis and halting of catabolism) which eventually leads to the accumulation of large amounts of fat (triglycerides) in liver cells, that if left untreated lead to inflammation and cirrhosis. This study aimed to investigate the effect of concomitant use of HESA-A and atorvastatin on bi...
متن کاملCurrent and emerging pharmacological therapy for non-alcoholic fatty liver disease
The main treatment of patients with non-alcoholic fatty liver disease (NAFLD) is life style modification including weight reduction and dietary regimen. Majority of patients are safely treated with this management and pharmacologic interventions are not recommended. However, a subgroup of NAFLD patients with non-alcoholic steatohepatitis (NASH) who cannot achieve goals of life style modificatio...
متن کاملSerum leptin levels in psoriatic patients with non-alcoholic fatty liver disease
Background: The prevalence of non-alcoholic fatty liver disease is higher in patients with psoriasis than in the normal population. Serum leptin levels are higher in patients with psoriasis and in patients with non-alcoholic fatty liver. The purpose of this study was to determine the serum levels of leptin in psoriatic patients with and without non-alcoholic fatty liver.<span...
متن کاملPharmacotherapy for Nonalcoholic Fatty Liver Disease.
Lifestyle modifications and optimization of the management of cardiometabolic comorbidities are currently the mainstay of treatment for patients with nonalcoholic fatty liver disease. Pharmacotherapy to halt or reverse hepatic histological injury and prevent the development of end-stage liver disease is specifically offered to patients with nonalcoholic steatohepatitis (NASH) and those with adv...
متن کاملAssociation of Non-Alcoholic Fatty Liver Dis-ease and Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus: a Cross-Sectional Study
Background: Diabetic retinopathy is a common chronic complication of diabetes and one of the leading causes of acquired blindness in the world. There is growing evidence that traditional risk factors do not fully justify the onset and progression of diabetic retinopathy. Therefore, some other risk factors such as non-alcoholic fatty liver disease may be involved in the pathophysiology of diabe...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 13 شماره
صفحات -
تاریخ انتشار 2017